Paper39201643
CD47 and IFT57 Are Colinear Genes That Are Highly Coexpressed in Most Cancers and Exhibit Parallel Cancer-Specific Correlations with Survival.
Dong K and 5 others. Int J Mol Sci, 2024. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. CD47 and IFT57 Are Colinear Genes That Are Highly Coexpressed in Most Cancers and Exhibit Parallel Cancer-Specific Correlations with Survival. Papers, record 39201643. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39201643
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- CD47 and IFT57 Are Colinear Genes That Are Highly Coexpressed in Most Cancers and Exhibit Parallel Cancer-Specific Correlations with Survival.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| CD47 Antigen | Major topic |
| Gene Expression Regulation, Neoplastic | Major topic |
| Adaptor Proteins, Signal Transducing | Major topic |
| Humans | |
| Cell Line, Tumor | |
| Gene Expression Profiling | |
| Neoplasms | |
| RNA, Messenger | |
| Thyroid Neoplasms |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| Z01 SC009172 | Intramural NIH HHS | United States | Z01SC009172 | PubMed | NIH RePORTER |
| ZIA SC009172 | Intramural NIH HHS | United States | ZIASC009172 | PubMed | NIH RePORTER |
References46
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31181609 | AXL Is a Novel Predictive Factor and Therapeutic Target for Radioactive Iodine Refractory Thyroid Cancer. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/31181609 | PubMed |
| 2 | 26840086 | A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer. | Oncotarget | 2016 | https://conductscience.org/library/papers/26840086 | PubMed |
| 3 | 30643501 | CD47 Expression in Natural Killer Cells Regulates Homeostasis and Modulates Immune Response to Lymphocytic Choriomeningitis Virus. | Front Immunol | 2018 | https://conductscience.org/library/papers/30643501 | PubMed |
| 4 | 21343401 | Activation of TYRO3/AXL tyrosine kinase receptors in thyroid cancer. | Cancer Res | 2011 | https://conductscience.org/library/papers/21343401 | PubMed |
| 5 | 35301709 | Checkpoint CD47 expression in classical Hodgkin lymphoma. | Br J Haematol | 2022 | https://conductscience.org/library/papers/35301709 | PubMed |
| 6 | 36882648 | The DNA damage response pathway regulates the expression of the immune checkpoint CD47. | Commun Biol | 2023 | https://conductscience.org/library/papers/36882648 | PubMed |
| 7 | 31628526 | Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of mice bearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation. | Cancer Immunol Immunother | 2019 | https://conductscience.org/library/papers/31628526 | PubMed |
| 8 | 24215318 | The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target. | Annu Rev Immunol | 2014 | https://conductscience.org/library/papers/24215318 | PubMed |
| 9 | 8864123 | Decreased resistance to bacterial infection and granulocyte defects in IAP-deficient mice. | Science | 1996 | https://conductscience.org/library/papers/8864123 | PubMed |
| 10 | 24157548 | Genome engineering using the CRISPR-Cas9 system. | Nat Protoc | 2013 | https://conductscience.org/library/papers/24157548 | PubMed |
| 11 | 37796823 | RAMP1 as a novel prognostic biomarker in pan-cancer and osteosarcoma. | PLoS One | 2023 | https://conductscience.org/library/papers/37796823 | PubMed |
| 12 | 17914110 | A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping. | Endocr Relat Cancer | 2007 | https://conductscience.org/library/papers/17914110 | PubMed |
| 13 | 31068700 | Next-generation characterization of the Cancer Cell Line Encyclopedia. | Nature | 2019 | https://conductscience.org/library/papers/31068700 | PubMed |
| 14 | 32043750 | Association between CD47 expression, clinical characteristics and prognosis in patients with advanced non-small cell lung cancer. | Cancer Med | 2020 | https://conductscience.org/library/papers/32043750 | PubMed |
| 15 | 30622229 | Loss of Primary Cilia Results in the Development of Cancer in the Murine Thyroid Gland. | Mol Cells | 2019 | https://conductscience.org/library/papers/30622229 | PubMed |
| 16 | 34079292 | Silencing HIPPI Suppresses Tumor Progression in Non-Small-Cell Lung Cancer by Inhibiting DNA Replication. | Onco Targets Ther | 2021 | https://conductscience.org/library/papers/34079292 | PubMed |
| 17 | 7998989 | Isolation and characterization of CD47 glycoprotein: a multispanning membrane protein which is the same as integrin-associated protein (IAP) and the ovarian tumour marker OA3. | Biochem J | 1994 | https://conductscience.org/library/papers/7998989 | PubMed |
| 18 | 28258703 | The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer. | Immunol Rev | 2017 | https://conductscience.org/library/papers/28258703 | PubMed |
| 19 | 31114875 | GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. | Nucleic Acids Res | 2019 | https://conductscience.org/library/papers/31114875 | PubMed |
| 20 | 25230070 | Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients. | Oncotarget | 2014 | https://conductscience.org/library/papers/25230070 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42007973 | CD47 promotes mitogen-activated protein kinase and epithelial-to-mesenchymal transition molecular programs to drive prometastatic phenotypes in non-small cell lung cancer. | Mol Oncol | 2026 | https://conductscience.org/library/papers/42007973 | PubMed |
| 39652550 | CD47 expression in non-small cell lung cancer and its relationship with tumor-associated macrophage infiltration. | PLoS One | 2024 | https://conductscience.org/library/papers/39652550 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD47 | 961 | PubTator's text mining | https://conductscience.org/library/genes/961 | NCBI Gene |
| CRACD | 57482 | PubTator's text mining | https://conductscience.org/library/genes/57482 | NCBI Gene |
| IFT57 | 55081 | PubTator's text mining | https://conductscience.org/library/genes/55081 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39201643
GET https://conductscience.org/api/papers/v1/39201643/references?page=2